Use of Immunosuppressive Therapy for Sarcoidosis

Outcome of Use of Cytotoxic Drugs for Inflammatory Lung Diseases

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02356445

Enrollment

2000

Registered

2015-02-05

Start date

2014-11-30

Completion date

2018-12-31

Last updated

2017-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoidosis

Brief summary

Retrospective review of the outcome of use of immunosuppressive drugs in treatment of sarcoidosis

Detailed description

Patients receiving one or more cytotoxic or other immunosuppressive drug will be observed

Interventions

OTHERCytotoxic drug

Observe patients versus treatment type

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 90 Years

Healthy volunteers

Inclusion criteria

Any patient treated for sarcoidosis

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Clinical Outcome	2 years	Number of participants with improvement over two years

Secondary

Measure	Time frame	Description
Toxicity	2 years	Number of participants with adverse events

Countries

United States

Contacts

Primary ContactRobert P Baughman, MD

bob.baughman@uc.edu513-584-5225

Backup ContactFelicia Thompson

thompsonf@ucmail.uc.edu513-584-5226

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026